ALB Albemarle Corporation

8-K Current Report

Filed: March 6, 2026

Health Care

Plastic Materials, Synth Resins & Nonvulcan Elastomers

Albemarle Corporation (ALB) 8-K current report filed with SEC EDGAR on March 6, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
3 items

Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 2.01 · Completion of Acquisition or Disposition of Assets

• Albemarle completed sale of 51% stake in Ketjen (catalyst business) to KPS Capital Partners on March 2, 2026
• Cash proceeds ~$547M from Ketjen sale, including $22M cash transferred with the business

+3 more insights

Item 7.01 · Regulation FD Disclosure

• Albemarle announced sale of its ownership interests in Ketjen, its refining catalyst business unit
• Ketjen divestiture signals continued portfolio optimization — Albemarle focusing capital on core lithium and specialty chemicals segments

+1 more insights

Item 8.01 · Other Events

• Redeeming 4.650% Senior Notes due 2027 in full — eliminates near-term maturity obligation
• Tender offer for up to $500M aggregate across four note series: 5.65% 2052, 5.45% 2044, 3.45% 2029 (subsidiary), and 5.05% 2032

+1 more insights

Other Albemarle Corporation 8-K Filings

8-K Mar 4, 2026

Get deeper insights on Albemarle Corporation

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.